WT1 and acute myeloid leukemia: The incidence of relapse was higher in AML patients with PB-WT1 ≥ 5 measured at the 3rd (56% versus 38%; P = 0.43) and the 6th month (71% versus 20%; P = 0.03) after allo-SCT.